INFIQ — Infinity Pharmaceuticals Share Price
Last trade - 00:00- $0.00m
- -$17.75m
- $2.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -458.62% | ||
| Return on Equity | n/a | ||
| Operating Margin | -1636.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.15 | 3.05 | 1.72 | 1.86 | 2.59 | 2.7 | 3.5 | -15.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Directors
- Adelene Perkins CHM (61)
- Lawrence Bloch PRE (55)
- Seth Tasker SVP (42)
- Stephane Peluso CSO
- Robert Ilaria OTH
- Norman Selby LED (69)
- Samuel Agresta DRC (49)
- Brian Schwartz DRC (49)
- David Beier IND (73)
- Anthony Evnin IND (80)
- Richard Gaynor IND (71)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- May 11th, 2000
- Public Since
- July 27th, 2000
- No. of Shareholders
- 46
- No. of Employees
- 30
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 90,761,081
- Address
- 1100 Massachusetts Avenue, Floor 4, CAMBRIDGE, 02138
- Web
- https://www.infi.com/
- Phone
- +1 6174531000
- Auditors
- Ernst & Young LLP
Upcoming Events for INFIQ
Similar to INFIQ
1PM Industries
Pink Sheets on Nasdaq
3Dshopping.Com
Pink Sheets on Nasdaq
3 Sixty Risk Solutions
Pink Sheets on Nasdaq
Adecco AG
Pink Sheets on Nasdaq
Adm Endeavors
Pink Sheets on Nasdaq
FAQ
As of Today at 21:18 UTC, shares in Infinity Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Infinity Pharmaceuticals last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Infinity Pharmaceuticals share price has underperformed the S&P500 Index by -6.57% over the past year.
The overall consensus recommendation for Infinity Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreInfinity Pharmaceuticals does not currently pay a dividend.
Infinity Pharmaceuticals does not currently pay a dividend.
Infinity Pharmaceuticals does not currently pay a dividend.
To buy shares in Infinity Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Infinity Pharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for Infinity Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: INFIQ
Based on an overall assessment of its quality, value and momentum Infinity Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Infinity Pharmaceuticals is $0.30. That is 29999900% above the last closing price of $0.00.
Analysts covering Infinity Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.46 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Infinity Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Infinity Pharmaceuticals were trading -99.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Infinity Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Infinity Pharmaceuticals' management team is headed by:
- Adelene Perkins - CHM
- Lawrence Bloch - PRE
- Seth Tasker - SVP
- Stephane Peluso - CSO
- Robert Ilaria - OTH
- Norman Selby - LED
- Samuel Agresta - DRC
- Brian Schwartz - DRC
- David Beier - IND
- Anthony Evnin - IND
- Richard Gaynor - IND